7月28日电，基石药业在港交所公告，将在欧洲肿瘤内科学会（ESMO）大会上公布研发管线2.0重磅产品CS2009（PD1/VEGF/CTLA-4三特异性抗体）的最新临床研究数据和CS5001（ROR1ADC）的全球多中心Ib期研究设计。

Core Viewpoint - The company, Basilea Pharmaceutica, announced that it will present the latest clinical research data for its key product CS2009 (a PD1/VEGF/CTLA-4 tri-specific antibody) and the global multi-center Phase Ib study design for CS5001 (ROR1ADC) at the ESMO conference [1] Group 1 - Basilea will unveil significant clinical research findings for CS2009 at the ESMO conference [1] - The company will also present the study design for CS5001, indicating ongoing development in its pipeline [1]